• October 12, 2023

All Three Athos Co-Founders Named to Stanford’s List of the World’s Top 2% of Scientists

• May 17, 2023

Tony Zingale, Noted Chief Executive Officer and Entrepreneur, Appointed as an Observer to the Board of Directors of Athos Therapeutics

• April 27, 2023

Athos Therapeutics Announces Dosing of the First Patient in the First-In-Human Phase 1 Clinical Trial of ATH-063

• April 19, 2023

Athos Therapeutics Announces Research Collaboration with the University of Ioannina to Advance the Field of Inflammatory Bowel Disease

• March 29, 2023

Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063

• August 25, 2022

Athos Therapeutics Announces Proteomics Research Collaboration for Inflammatory Bowel Disease with Caltech

• July 11, 2022

Athos Therapeutics Announces Research Collaboration to Advance Precision Medicine in Inflammatory Bowel Disease

• May 18, 2022

Abraham Verghese MD, Noted Stanford Physician and Recipient of the National Humanities Medal at the White House from former President Obama, Appointed to the Board of Directors of Athos Therapeutics

• November 22, 2021

Athos Therapeutics Announces the Completion of its Oversubscribed Series A Financing

• August 24, 2021

Athos Therapeutics Announces Research Collaboration with Cleveland Clinic to Advance Precision Medicine in Inflammatory Bowel Disease